Immunotherapy drug nivolumab shows potential to fight against Advanced Liver Cancer Study was conducted in 11 countries, including Singapore led by NCCS Nivolumab is the first immune-oncology drug to be approved by US FDA for 2nd line therapy in advanced HCC after sorafenib as a result of this study Phase 3 study comparing nivolumab with […]
Related Articles
The post Multi-centre trial paves way for immunotherapy in Advanced Liver cancer appeared first on Biotechin.Asia.
This post first appeared on Biotechin.asia – Your Daily Biotech And Healthca, please read the originial post: here
